|
|
|
|
LEADER |
03907nam a2200685Ia 4500 |
001 |
10.47391-JPMA.2413 |
008 |
220630s2022 CNT 000 0 und d |
020 |
|
|
|a 00309982 (ISSN)
|
245 |
1 |
0 |
|a The relationship between albumin-bilirubin score and survival in patients operated for pancreatic cancer
|
260 |
|
0 |
|b Pakistan Medical Association
|c 2022
|
520 |
3 |
|
|a Objective: To investigate whether albumin-bilirubin score can be used as a prognostic marker in pancreatic cancer patients post-surgery. Method: The retrospective study was conducted at the Medical Oncology Clinic, Karadeniz Technical University, Trabzon, Turkey, and comprised data from 2010 to 2018 of pancreatic cancer patients who had undergone distal pancreatectomy or pancreaticoduodenectomy and were followed up for 3 years. Preoperative and postoperative serum albumin, carcinoembryonic antigen, carbohydrate antigen 19-9, bilirubin, neutrophil: lymphocyte ratio and platelet: lymphocyte ratio were compared as inflammation markers, while albumin-bilirubin scores were calculated using the equation linear predictor. Data was analysed using SPSS 17. Results: Of the 39 patients, 23(59%) were men and 16(41%) were women. The mean age of the sample was 62.4±10.2 years. No statistically significant changes were observed between preoperative and postoperative albumin-bilirubin scores, carcinoembryonic antigen, neutrophil: lymphocyte ratio and platelet: lymphocyte ratio (p>0.05). Significant decreases were observed in postoperative carbohydrate antigen 19-9, aspartate transaminase and alanine transaminas levels (respectively<0.05). No significant change was determined in postoperative albumin-bilirubin grade distributions compared to preoperative values (p=0.180). Although the rate of recurrence increased in line with preoperative albumin-bilirubin scores, the finding was not statistically significant (p=0.055). Mortality rate increased significantly in line with preoperative albumin-bilirubin scores (p=0.013). Conclusion: The albumin-bilirubin score affected survival in patients with pancreatic cancer, and can be employed as a prognostic factor in this patient group. © 2022 Pakistan Medical Association. All rights reserved.
|
650 |
0 |
4 |
|a adult
|
650 |
0 |
4 |
|a alanine aminotransferase
|
650 |
0 |
4 |
|a albumin bilirubin score
|
650 |
0 |
4 |
|a albumin blood level
|
650 |
0 |
4 |
|a Albumin-bilirubin score
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a aspartate aminotransferase
|
650 |
0 |
4 |
|a bilirubin blood level
|
650 |
0 |
4 |
|a CA 19-9 antigen
|
650 |
0 |
4 |
|a cancer grading
|
650 |
0 |
4 |
|a cancer prognosis
|
650 |
0 |
4 |
|a cancer recurrence
|
650 |
0 |
4 |
|a cancer staging
|
650 |
0 |
4 |
|a carcinoembryonic antigen
|
650 |
0 |
4 |
|a comparative study
|
650 |
0 |
4 |
|a demographics
|
650 |
0 |
4 |
|a distal pancreatectomy
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a follow up
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a human tissue
|
650 |
0 |
4 |
|a inflammation
|
650 |
0 |
4 |
|a lymph node dissection
|
650 |
0 |
4 |
|a lymph node metastasis
|
650 |
0 |
4 |
|a male
|
650 |
0 |
4 |
|a middle aged
|
650 |
0 |
4 |
|a neutrophil lymphocyte ratio
|
650 |
0 |
4 |
|a pancreas adenocarcinoma
|
650 |
0 |
4 |
|a pancreas cancer
|
650 |
0 |
4 |
|a Pancreatic cancer
|
650 |
0 |
4 |
|a pancreaticoduodenectomy
|
650 |
0 |
4 |
|a pathology
|
650 |
0 |
4 |
|a platelet lymphocyte ratio
|
650 |
0 |
4 |
|a postoperative care
|
650 |
0 |
4 |
|a preoperative evaluation
|
650 |
0 |
4 |
|a Prognostic factors
|
650 |
0 |
4 |
|a retrospective study
|
650 |
0 |
4 |
|a scoring system
|
650 |
0 |
4 |
|a statistical analysis
|
650 |
0 |
4 |
|a surgical margin
|
650 |
0 |
4 |
|a survival analysis
|
650 |
0 |
4 |
|a Turkey (republic)
|
700 |
1 |
0 |
|a Cekic, A.B.
|e author
|
700 |
1 |
0 |
|a Fidan, E.
|e author
|
700 |
1 |
0 |
|a Fidan, S.
|e author
|
700 |
1 |
0 |
|a Kazaz, N.
|e author
|
700 |
1 |
0 |
|a Yildirim, A.
|e author
|
773 |
|
|
|t Journal of the Pakistan Medical Association
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.47391/JPMA.2413
|